-
Something wrong with this record ?
Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study
P. Šmak, S. Chandrabose, I. Tvaroška, J. Koča
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
LQ1601
Ministry of Education, Youth and Sports of the Czech Republic
LM2018140
Large Infrastructures for Research, Experimental Development and Innovations
CZ.02.2.69/0.0/0.0/17_050/0008496
European Regional Development Fund
VEGA-02/0024/16
Scientific Grant Agency of the Ministry of Education
NLK
Free Medical Journals
from 1996 to 1 year ago
Open Access Digital Library
from 1996-01-01
Medline Complete (EBSCOhost)
from 1996-01-01 to 1 year ago
- MeSH
- Antiviral Agents chemistry MeSH
- Biomimetic Materials chemistry MeSH
- Databases, Chemical * MeSH
- COVID-19 MeSH
- COVID-19 Drug Treatment MeSH
- Humans MeSH
- Computer Simulation * MeSH
- Drug Evaluation, Preclinical MeSH
- SARS-CoV-2 chemistry metabolism MeSH
- Selectins chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the globe. The spectrum of disease is broad but among hospitalized patients with COVID-19, respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. There is an urgent need for an effective treatment. The current focus has been developing novel therapeutics, including antivirals, protease inhibitors, vaccines and targeting the overactive cytokine response with anti-cytokine therapy. The overproduction of early response proinflammatory cytokines results in what has been described as a "cytokine storm" is leading eventually to death when the cells fail to terminate the inflammatory response. Accumulating evidence shows that inflammatory cytokines induce selectin ligands that play a crucial role in the pathogenesis of inflammatory diseases by mediating leukocyte migration from the blood into the tissue. Thus, the selectins and selectin ligands represent a promising therapeutic target for the treatment of COVID-19. In this paper, potential pan-selectin inhibitors were identified employing a virtual screening using a docking procedure. For this purpose, the Asinex and ZINC databases of ligands, including approved drugs, biogenic compounds and glycomimetics, altogether 923,602 compounds, were screened against the P-, L- and E-selectin. At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose 10 purchasable pan-selectin inhibitors to develop COVID-19 therapeutics.
Central European Institute of Technology Masaryk University 625 00 Brno Czech Republic
Institute of Chemistry Slovak Academy of Sciences 845 38 Bratislava Slovak Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024960
- 003
- CZ-PrNML
- 005
- 20211026134240.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/glycob/cwab021 $2 doi
- 035 __
- $a (PubMed)33822042
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Šmak, Pavel $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- 245 10
- $a Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study / $c P. Šmak, S. Chandrabose, I. Tvaroška, J. Koča
- 520 9_
- $a Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the globe. The spectrum of disease is broad but among hospitalized patients with COVID-19, respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. There is an urgent need for an effective treatment. The current focus has been developing novel therapeutics, including antivirals, protease inhibitors, vaccines and targeting the overactive cytokine response with anti-cytokine therapy. The overproduction of early response proinflammatory cytokines results in what has been described as a "cytokine storm" is leading eventually to death when the cells fail to terminate the inflammatory response. Accumulating evidence shows that inflammatory cytokines induce selectin ligands that play a crucial role in the pathogenesis of inflammatory diseases by mediating leukocyte migration from the blood into the tissue. Thus, the selectins and selectin ligands represent a promising therapeutic target for the treatment of COVID-19. In this paper, potential pan-selectin inhibitors were identified employing a virtual screening using a docking procedure. For this purpose, the Asinex and ZINC databases of ligands, including approved drugs, biogenic compounds and glycomimetics, altogether 923,602 compounds, were screened against the P-, L- and E-selectin. At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose 10 purchasable pan-selectin inhibitors to develop COVID-19 therapeutics.
- 650 _2
- $a antivirové látky $x chemie $7 D000998
- 650 _2
- $a biomimetické materiály $x chemie $7 D040761
- 650 _2
- $a COVID-19 $7 D000086382
- 650 12
- $a počítačová simulace $7 D003198
- 650 12
- $a chemické databáze $7 D062126
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a SARS-CoV-2 $x chemie $x metabolismus $7 D000086402
- 650 _2
- $a selektiny $x chemie $7 D019087
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chandrabose, Selvaraj $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Tvaroška, Igor $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $u Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovak Republic
- 700 1_
- $a Koča, Jaroslav $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
- 773 0_
- $w MED00001937 $t Glycobiology $x 1460-2423 $g Roč. 31, č. 8 (2021), s. 975-987
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33822042 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134246 $b ABA008
- 999 __
- $a ok $b bmc $g 1714140 $s 1145467
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 31 $c 8 $d 975-987 $e 20210909 $i 1460-2423 $m Glycobiology $n Glycobiology $x MED00001937
- GRA __
- $a LQ1601 $p Ministry of Education, Youth and Sports of the Czech Republic
- GRA __
- $a LM2018140 $p Large Infrastructures for Research, Experimental Development and Innovations
- GRA __
- $a CZ.02.2.69/0.0/0.0/17_050/0008496 $p European Regional Development Fund
- GRA __
- $a VEGA-02/0024/16 $p Scientific Grant Agency of the Ministry of Education
- LZP __
- $a Pubmed-20211013